AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting

by Barry101 | Mar 9, 2022 | Press Release, Uncategorized

OCALA, Fla., March 09, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer

by Barry101 | Mar 8, 2022 | Press Release, Uncategorized

Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center Treatment with Ampligen following FOLFIRINOX...

AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline

by Barry101 | Mar 7, 2022 | Press Release, Uncategorized

OCALA, Fla., March 07, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer

by Barry101 | Mar 3, 2022 | Press Release, Uncategorized

Industry veteran and financial and strategic leader with deep capital markets and business development transactional expertise across life science and medical device companiesOCALA, Fla., March 03, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM)...

AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar

by Barry101 | Jan 26, 2022 | Press Release, Uncategorized

AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm – 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long...

AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

by Barry101 | Jan 24, 2022 | Press Release, Uncategorized

Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function Strength of data support advancement into Phase 2 clinical...